ChemicalBook > CAS DataBase List > Lapatinib ditosylate

Lapatinib ditosylate

Product Name
Lapatinib ditosylate
CAS No.
388082-78-8
Chemical Name
Lapatinib ditosylate
Synonyms
Lapatinib ditosylate Monohydrate;Lapatinib tosilate;Lapatinib ditosylate hydrate;Lapatinb;GW2016 ditosylate;GW-572016;GW572016;(E)-Ferulic acid-d;lapatinib(GW572016);Lapatinib Ditosilate;Lapatinib ditosylate
CBNumber
CB2966227
Molecular Formula
C41H40ClFN4O11S3
Formula Weight
925.46
MOL File
388082-78-8.mol
More
Less

Lapatinib ditosylate Property

Melting point:
>200oC (dec.)
storage temp. 
under inert gas (nitrogen or Argon) at 2-8°C
solubility 
DMSO (Slightly), Methanol (Slightly)
form 
Solid
color 
Yellow
CAS DataBase Reference
388082-78-8(CAS DataBase Reference)
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

TRC
Product number
L175813
Product name
LapatinibDitosylateMonohydrate
Packaging
10mg
Price
$85
Updated
2021/12/16
Usbiological
Product number
281198
Product name
Lapatinib ditosylate
Packaging
50mg
Price
$375
Updated
2021/12/16
Usbiological
Product number
015474
Product name
Lapatinib Ditosylate
Packaging
5mg
Price
$425
Updated
2021/12/16
Matrix Scientific
Product number
090594
Product name
Lapatinib ditosylate hydrate
Purity
98%
Packaging
250mg
Price
$567
Updated
2021/12/16
Biorbyt Ltd
Product number
orb180754
Product name
Lapatinib ditosylate
Purity
>98%
Packaging
250mg
Price
$615.4
Updated
2021/12/16
More
Less

Lapatinib ditosylate Chemical Properties,Usage,Production

Uses

anticancer

Uses

binds to a(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors atypical antipsychotic agent

Uses

Lapatinib ditosylate monohydrate is a form of Lapatinib I, an orally active drug for breast cancer as a dual EGFR and erbB-?2 inhibitor.

Definition

ChEBI: Lapatinib ditosylate monohydrate is a member of quinazolines.

General Description

Lapatinib is available in 250-mg tablets for oral administrationand is used in combination with cabecitabine in thetreatment of breast cancer for those patients that over expressthe type 2 EGF-R and who have previously receivedtaxane, anthracycline, and trastuzumab therapy. The type 2EGF-R is one subtype of this receptor and is also known asHER2 or ErbB-2. The agent is a receptor TK inhibitor targetingthe ErbB-1 and ErbB-2 subtypes. Binding occurs atthe ATP-binding site and thereby prevents phosphorylationand the subsequent activation of other kinase enzymes.ErbB-1 overexpression occurs in approximately27% to 30% of breast cancers, while ErbB-2 is over expressedin 20% to 25% of cases.The agent has demonstratedIC50 values of <0.2μM against ErbB-1 and 2 fromseveral different cancer cell lines and dissociates slowly(t1/2=300 min) from these receptor TKs.The drug isboth a substrate and an inhibitor of the efflux transportersPgp and BCRP. It is also an inhibitor of the hepatic uptaketransporter OATP1B1, which is an organic anion transporter.The absorption of lapatinib is incomplete andvariable after oral administration. The agent is extensivelymetabolized by CYP3A4 and CYP3A5, with minor contributionsfrom CYP2C19 and CYP2C8. Lapatinib inhibitsCYP3A and CYP2C8 at clinically relevant concentrations.The agent is highly (99%) protein bound and eliminatedprimarily in the feces. The half-life of the agent increaseupon repeated dosing, taking 6 days to reach steady statethat gives an effective half-life of 24 hours. The most commonlyseen adverse effects of lapatinib therapy are skinrash and diarrhea. Skin rash is commonly seen with manyof the other TK inhibitors and agents that target ErbB-1.Lapatinib-induced diarrhea is usually mild to moderate.There have been reports of decreases in left ventricularejection fraction associated with the agent, although thisappears to occur only rarely and is reversible upon discontinuationof therapy.

target

EGFR

Lapatinib ditosylate Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Lapatinib ditosylate Suppliers

R&D Scientific Inc.
Tel
+1-2266000236
Email
sales@rdscientific.com
Country
Canada
ProdList
1603
Advantage
58
More
Less

View Lastest Price from Lapatinib ditosylate manufacturers

hebei hongtan Biotechnology Co., Ltd
Product
Lapatinib ditosylate 388082-78-8
Price
US $30.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
2000kg
Release date
2024-05-13
HangZhou RunYan Pharma Technology Co.,LTD.
Product
Lapatinib ditosylate 388082-78-8
Price
US $0.00-0.00/g
Min. Order
1g
Purity
99% HPLC
Supply Ability
10000
Release date
2024-09-17
Nanjing Fred Technology Co., Ltd
Product
Lapatinib Ditosylate 388082-78-8
Price
US $0.00-0.00/kg
Min. Order
1kg
Purity
99%,single impurity<0.1
Supply Ability
1 ton
Release date
2023-12-29

388082-78-8, Lapatinib ditosylateRelated Search:


  • Lapatinib ditosylate
  • benzenesulfonic acid: N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6 -[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine: h ydrate
  • N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine bis(4-methylbenzenesulfonate)
  • Lapatinib Ditosilate
  • Lapatinib, Tykerb, GW572016
  • Lapatinib Ditosylate (GW-572016)
  • lapatinib(GW572016)
  • Lapatinib ditosylate hydrate
  • bis(N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(Methylsulfonyl)ethylaMino)Methyl)furan-2-yl)quinazolin-4-aMine) tetrakis(4-Methylbenzenesulfonate) hydrate
  • Lapatinb
  • 4-QuinazolinaMine, N-[3-chloro-4-[(3-fluorophenyl)Methoxy]phenyl]-6-[5-[[[2-(Methylsulfonyl)ethyl]aMino]Methyl]-2-furanyl]-, bis(4-Methylbenzenesulfonate), Monohydrate (9CI)
  • Lapatinib ditosylate Monohydrate
  • Rapatinib bis - toluene sulfonate
  • GW-572016;GW572016
  • Lapatinib xylene sulfonate
  • N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine, 4-methylbenzenesulfonate, hydrate (1:2:1)
  • Lapatinib Ditosylate MonohydrateI
  • N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine bis(4-methylbenzenesulfonate) monohydrate
  • Lapatinib ditosylate hydrat
  • 4-QuinazolinaMine, N-[3-chloro-4-[(3-fluorophenyl)Methoxy]phenyl]-6-[5-[[[2-(Methylsulfonyl)ethyl]aMino]Methyl]-2-furanyl]-, bis(4-Methylbenzenesulfonate), Monohydrate
  • xyene sulfonate lapatinib
  • (N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(Methylsulfonyl)ethylaMino)Methyl)furan-2-yl)quinazolin-4-aMine)bis(4-Methylbenzenesulfonate) hydrate
  • Lapatinib ditosylate N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine bis(4-methylbenzenesulfonate)
  • N-(3-Chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)-quinazolin-4-ylamine ditosylate hydrate
  • Lapatinib ditoluenesulfonate monohydrate
  • Lapatinib tosilate
  • Lapatinib tosilate hydrate
  • Lapatinib ditosylate ISO 9001:2015 REACH
  • Lapatinib D4 DitosylateQ: What is Lapatinib D4 Ditosylate Q: What is the CAS Number of Lapatinib D4 Ditosylate
  • Lapatinib p-toluenesulfonate monohydrate
  • GW2016 ditosylate
  • (E)-Ferulic acid-d
  • Lapatinib ditosylate monohydrate|||Lapatinib ditoluenesulfonate monohydrate|||Lapatinib tosilate hydrate|||Lapatinib tosilate|||Tykerb|||Tyverb
  • 388082-78-8
  • 388083-78-8
  • 388082-78-9
  • C29H26ClFN4O4S2C7H8O3
  • C29H26ClFN4O4S2C7H8O3S
  • C41H40ClFN4O11S3
  • C29H26ClFN4O4S2C74H8O3SH2O
  • 2C7H8O3SC29H26ClFN4O4S
  • C29H26ClFN4O4S2C7H8O3SH2O
  • C43H44ClFN4O11S3
  • anti-neoplastic
  • Inhibitors
  • Anti-cancer&immunity
  • Lapatinib
  • API
  • 388082-78-8